Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Dapagliflozin vs Metformin: they're closely matched on evidence (4.4 vs 4/10); they're alternatives for manage blood sugar — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Dapagliflozin and Metformin are closely matched across evidence, studies, and safety.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Off-label use mirrors approved dosing (10 mg once daily) under a clinician. A prescription drug; not an approved longevity regimen.
morning
Oral tablet (dapagliflozin)
Off-label longevity use mirrors diabetes dosing (commonly 500–1500 mg/day of extended-release with meals) under a clinician. Not an approved longevity regimen, and unnecessary in well-controlled non-diabetics without a clear rationale.
with-meals
Extended-release tablet
Months to years
Months to years
Weeks to months
Throughout use
Weeks
Years
Weeks of training
Days (GI) to years (B12)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
The New England journal of medicine (2019) · Rct · n=4744
DAPA-HF randomized trial in heart failure with reduced ejection fraction
Dapagliflozin in Patients with Chronic Kidney Disease.
The New England journal of medicine (2020) · Rct · n=4304
DAPA-CKD randomized trial in a broad, largely non-diabetic chronic-kidney-disease population
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.
The New England journal of medicine (2022) · Rct · n=6263
DELIVER randomized trial extending dapagliflozin to mildly reduced and preserved ejection fraction
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Lancet (London, England) (1998) · Rct · n=753
UKPDS 34 randomized trial of metformin in overweight type-2 diabetics
Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: A systematic review and meta-analysis.
Ageing research reviews (2017) · Meta analysis
Systematic review/meta-analysis of metformin and age-related outcomes
Metformin as a Tool to Target Aging.
Cell metabolism (2016) · Review
Review of metformin's aging-relevant mechanisms (AMPK, insulin/IGF-1, inflammation)
Both Dapagliflozin and Metformin are closely matched — the best choice depends on your specific health goals.
For manage blood sugar, Metformin has a higher relevance score (72 vs 60).
No known interactions between Dapagliflozin and Metformin have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.